MYC overexpression correlated with poor prognosis in sporadic breast cancer with susceptibility gene 1 (BRCA1) deficiency with a TNBC phenotype [42], and thus, a combination therapy targeting BRCA1 deficiency and the MYC pathway may provide a promising strategy for this specific subtype of breast cancer. The gene discussed is MYC; the disease is breast cancer.